MI Cancer Seek Tumor Profiling

MI Cancer Seek

MI Cancer Seek™ is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.

FDA-Approved CDx Indications and Tumor Profiling

MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic device using total nucleic acid (TNA) isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens for the detection of SNVs, InDels, MSI, TMB in patients with previously diagnosed solid tumors, and CNA in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table, in accordance with the approved therapeutic product labeling.

Additional Services

Beyond the MI Cancer Seek FDA-approved indications, additional sequencing-based features are reported.

  • DNA: gLOH, HRD, HLA Genotype, Chromosomal Alterations, Viruses (HPV 16 & 18, EBV, MCPyV)
  • RNA: Expression, Fusions, Variant Transcripts
  • AI Signatures: Caris GPSai™, Caris FOLFIRSTai™

MI Cancer Seek will be available for clinical ordering soon. 

SPECIMEN TYPE

Tissue (FFPE)

APPLICATION

Solid tumor profiling for therapy selection

DOCUMENT DOWNLOADS

Technical Information

MI Cancer Seek Companion Diagnostic Indications

Indication

Biomarker

Therapy

Breast Cancer

PIK3CA (C420R; E542K; E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and H1047L, H1047R, H1047Y)

PIQRAY® (alpelisib)

Colorectal Cancer (CRC)

KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)

VECTIBIX® (panitumumab)

BRAF V600E

BRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab)

Melanoma

BRAF V600E

BRAF inhibitors approved by FDA*

BRAF V600E or V600K

MEKINIST® (trametinib) or BRAF/MEK inhibitor combinations approved by FDA*

Non-Small Cell Lung Cancer (NSCLC)

EGFR exon 19 deletions and exon 21 L858R alterations

EGFR Tyrosine Kinase Inhibitors approved by FDA*

Solid Tumors

MSI-H

KEYTRUDA® (pembrolizumab), JEMPERLI (dostarlimab-gxly)

Endometrial Carcinoma

Not MSI-H

KEYTRUDA® (pembrolizumab) in combination with LENVIMA® (lenvatinib)

*For the most current information about the device indications for the therapeutic products in this group, go to:
https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools#Group_Labeling

PIQRAY® is a registered trademark of Novartis AG. VECTIBIX® is a registered trademark of Immunex Corporation. BRAFTOVI® is a registered trademark of Array BioPharma Inc. in the United States and various other countries. ERBITUX® is a registered trademark of ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company. MEKINIST® is a registered trademark of Novartis AG Corporation Switzerland. KEYTRUDA® is a registered trademark of Merck. LENVIMA® (lenvatinib) is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

MI Cancer Seek - Technical Specifications and Performance

CLS-MI-Cancer-Seek-Box-2_afd41f

TECHNOLOGY

Next-generation sequencing of total nucleic acids

VARIANT COVERAGE

Somatic Tumor:

SNVs  InDels  CNAs

GENOMIC SIGNATURES

MSI  TMB

SPECIMEN QUANTITY

TNA extraction with
≥50 ng of DNA

(~10 slides at 20% tumor nuclei)

BREAST

PIK3CA PPA: 99.4%
NPA: 100%
   

CRC

KRAS & NRAS
Wild-type
PPA: 100%
NPA: 97.2%
   
BRAF V600E PPA: 99.4%
NPA: 100%

MELANOMA

BRAF V600E PPA: 98.7%
NPA: 99.4%
   
BRAF V600E/K PPA: 98.9%
NPA: 99.3%

NSCLC

EGFR exon 19 deletions
and exon 21 L858R alterations
PPA: 98.1%
NPA: 99.4%

Solid Tumors

MSI-H PPA: 97.5%
NPA: 98.5%

Endometrial

Not MSI-H PPA: 98.4%
NPA: 97.6%

TNA extraction with ≥50 ng of DNA is the minimum assay input requirement to perform MI Cancer Seek™. If insufficient quantity is submitted (<50 ng), the order for MI Cancer Seek will automatically reflex to MI Tumor Seek Hybrid™ (LDT).

Intended Use

MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer.

MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table, in accordance with the approved therapeutic product labeling.

Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.

Enhance Molecular Insights with Additional Services

MI Cancer Seek is a single assay that analyzes total nucleic acids for both DNA and RNA. Typically, DNA and RNA analysis by NGS requires two separate testing processes, which may require more tissue and more time. By combining WES and WTS into one assay, however, MI Cancer Seek provides a comprehensive molecular blueprint that saves tissue without compromising results.

Comprehensive Professional Services Art_300ppi 1
MI-Cancer-Seek-Sample-Report

Easy-to-Interpret Results
for Clarity in Treatment Planning

Treatment Planning:

  • Navigate among FDA-approved drugs and therapies with potential benefit or lack of benefit
  • Identify therapies that may not have been considered
  • Match patient to clinical trials based on tumor biology

Evidence-guided:

  • Drug associations based on peer-reviewed literature and clinical treatment guidelines
  • Testing methodologies consistent with industry guidelines

EHR Compatible:

  • HITECH compliant
  • Easy installation
  • Secure encryption
  • Real-time sync

Technical Information

For complete product information, including companion diagnostic indications and performance characteristics, view the Technical Information document.

Testing Menu

It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors.
LEARN MORE

Resources

Caris' resources provide valuable information about precision oncology and advancing cancer care.
LEARN MORE